Atea Pharmaceuticals Inc.

Address: 225 Franklin Street Suite 2100

Sponsor Overview

assignment

Specializations

COVID-19 Outpatient Treatment

Research activity includes COVID-19 in high-risk outpatients, with attention to reducing hospitalization and mortality in individuals receiving supportive care.

Antiviral therapy
Outpatient management
Hospitalization prevention
Mortality reduction

The sponsor’s clinical focus in this area centers on treatment options for symptomatic viral infection outside the hospital setting.

Chronic Hepatitis C Virus Infection

Clinical research also addresses chronic hepatitis C virus infection, with emphasis on achieving sustained virologic response and supporting viral eradication in infected patients.

Hepatitis C treatment
Virologic response
Viral suppression
Curative antiviral strategies

This area reflects sustained interest in therapies directed at long-term control of HCV infection.

Direct-Acting Antiviral Development

The sponsor’s trial portfolio includes investigation of direct-acting antivirals used in both respiratory and hepatic viral diseases, with particular attention to oral treatment approaches.

Oral antiviral regimens
Combination antiviral therapy
Viral replication inhibition
Tolerability assessment

These studies align with the sponsor’s interest in medicines designed to target viral pathways across distinct infectious diseases.

Infectious Disease Clinical Research

The sponsor is active in infectious disease research across multiple countries and collaborating sites, supporting clinical evaluation in broad viral disease settings.

Viral infection
Supportive care settings
Multinational study activity
Clinical antiviral evaluation

This research footprint spans both acute and chronic viral illnesses.

Trial Name	Country	Status
Evaluation of Bemnifosbuvir Hemisulfate Efficacy and Safety in High-Risk COVID-19 Outpatients: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial	Germany Latvia Romania Spain Sweden The Netherlands	Not Recruiting
Phase 2 Open-Label Evaluation of Bemnifosbuvir Hemisulfate and Ruzasvir for Safety and Efficacy in Chronic Hepatitis C Virus Infection	Germany Romania Spain	Not Recruiting
Phase 3 Randomized Controlled Trial of Bemnifosbuvir-Ruzasvir Versus Sofosbuvir-Velpatasvir in Chronic Hepatitis C Virus Infection	France Germany Greece Poland Romania Spain	Not Recruiting
Safety and Pharmacokinetic Evaluation of Single and Multiple Oral Doses of AT-587 in Healthy Adults for Treatment of Chronic Hepatitis E Virus Infection	Belgium	Recruiting